Development and Testing of a Brief Tool to Assess Breakthrough Cancer Pain in Taiwan

November 10, 2026 updated by: Chang Gung Memorial Hospital

Development and Application of the Breakthrough Cancer Pain Assessment (BCPA) Tool for Cancer Patients in Taiwan

This study aims to develop and test a brief tool called the Breakthrough Cancer Pain Assessment (BCPA) for use with cancer patients in Taiwan. The tool is intended to help medical staff assess episodes of breakthrough cancer pain in busy clinical settings.

The study has three stages. First, 14 clinical experts will review an initial set of 11 questions and assess whether they are relevant and important. Second, two medical staff members will separately interview each of 30 patients within three hours on the same day and independently record the answers to evaluate agreement between their ratings. Third, the tool will be applied in 1,043 patients recruited from multiple hospitals who are receiving short-acting opioids other than Painkyl.

In the clinical application stage, physicians will prescribe and individually adjust fentanyl buccal soluble film (Painkyl) for patients whose breakthrough pain is not meaningfully relieved within 15 minutes or whose medication administration route needs adjustment. These patients will be reassessed with the BCPA one to two weeks later. Patients with satisfactory pain relief at the initial assessment will undergo no further study procedures.

The main objectives are to evaluate the content validity and inter-rater reliability of the BCPA. A secondary objective is to determine the percentage of patients reporting meaningful pain relief within or at 15 minutes after taking Painkyl.

The planned secondary assessments also compare the pretreatment and post-treatment percentages of patients reporting meaningful pain relief within 15 minutes and their usual breakthrough pain intensity. Relief is reported by the patient using BCPA item 9; pain intensity is assessed using BCPA item 6 on a 0-to-10 scale.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The protocol describes an open-label, multicenter study comprising tool development, inter-rater reliability testing, and clinical application of the Breakthrough Cancer Pain Assessment (BCPA).

An initial set of 11 items will be developed from the literature and the opinions of oncologists experienced in managing breakthrough cancer pain. Fourteen experts in breakthrough cancer pain and/or pain instrument development will rate item relevance and importance using a four-point scale. Experts will provide comments on items rated as not or somewhat relevant or important. A Delphi process, with a maximum of four rounds, will provide feedback on item ratings and content validity. Items may be modified or deleted based on the expert review. The Delphi assessment period was approximately one month.

For inter-rater reliability testing, two medical staff members will separately interview each of 30 patients from one study site within three hours on the same day and independently record the answers. Items with low agreement or consistency will be discussed and revised before clinical application.

The clinical application stage will recruit 1,043 patients from multiple hospitals who are receiving short-acting opioids other than Painkyl. The BCPA will be used at the initial assessment to evaluate breakthrough pain control. Patients with satisfactory pain relief will undergo no further study procedures. Patients with unsatisfactory control, defined as taking more than 15 minutes to achieve meaningful relief with their current breakthrough pain medication other than Painkyl, and/or requiring a change in medication administration route at the physician's discretion, will receive Painkyl with individual dose titration and education on its use. The protocol schedules the pretreatment assessment on Day 0-1, treatment initiation on Day 1, and reassessment on Day 8-15.

The research nurse will check completed BCPA questionnaires to minimize missing data. The protocol defines a full analysis set requiring at least one BCPA assessment and an evaluable-patient set requiring both pretreatment and post-treatment assessments, in addition to informed consent, eligibility, and no protocol violations.

BCPA Tool V1.2 (14-Apr-2023) item 9 asks the patient how long rescue medication takes to provide effective pain relief. Responses of 10 minutes or less, or more than 10 but no more than 15 minutes, indicate meaningful relief within 15 minutes. Responses of no effect or more than 15 minutes indicate that this criterion is not met. Pretreatment responses concern the existing rescue medication; post-treatment responses concern Painkyl. BCPA item 6 assesses usual breakthrough pain intensity on a 0-to-10 numeric scale, where 0 is no pain and 10 is the worst pain. Higher scores indicate greater pain intensity. The questionnaire does not specify a fixed recall period.

The protocol specifies a Cochran Q test to compare pretreatment and post-treatment meaningful-relief percentages and generalized estimating equations (GEE) to examine pretreatment and post-treatment pain intensity. These analyses supplement the post-treatment meaningful-relief percentage.

Study Type

Interventional

Enrollment (Estimated)

1073

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Kaohsiung City, Taiwan
        • Recruiting
        • Chang Gung Memorial Hospital, Kaohsiung
      • Keelung, Taiwan
        • Recruiting
        • Chang Gung Memorial Hospital, Keelung - Lovers Lake Branch
      • Taoyuan City, Taiwan
        • Recruiting
        • Chang Gung Memorial Hospital, Linkou
    • Chiayi County
      • Pozi, Chiayi County, Taiwan, 61363
        • Recruiting
        • Chang Gung Memorial Hospital, Chiayi

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female patients aged 18 years or older.
  • Breakthrough pain occurring on at least two days during the preceding two weeks, with no more than three episodes per day.
  • Opioid-tolerant patients with cancer who have received at least 60 mg/day of oral morphine equivalents for one week.

Additional Inclusion Criterion for the Clinical Application Stage (Stage 3):

- Patients must be receiving short-acting opioids other than Painkyl.

Exclusion Criteria:

  • High risk of opioid-induced respiratory depression, in the investigator's judgment.
  • Considered unsuitable for participation by the investigator.
  • Known pregnancy or breastfeeding.
  • Previous use of fentanyl buccal soluble film (Painkyl).
  • History of hypersensitivity or intolerance to fentanyl.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: BCPA-guided assessment and Painkyl treatment

In the clinical application stage, patients receiving short-acting opioids other than Painkyl undergo BCPA assessment. Those with unsatisfactory breakthrough pain control and/or requiring a change in medication administration route receive individually titrated Painkyl and a follow-up BCPA assessment. Patients with satisfactory pain relief at the initial assessment undergo no further study procedures. There is no comparator arm. The preceding tool-development stage includes a separate group of 30 patients. Two medical staff members separately interview each patient within three hours on the same day and independently record the answers for inter-rater reliability testing.

Fentanyl buccal soluble film (Painkyl) will be used for breakthrough cancer pain in patients whose current medication does not provide meaningful relief within 15 minutes and/or whose medication administration route requires adjustment. The dose will be individually titrated by the physician, starting at 200 mcg. The protocol specifies a maximum dose of 1,200 mcg per breakthrough pain episode. Patients will receive education on proper use and will be reassessed with the BCPA one to two weeks later.

Other Names:
  • Painkyl

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Item-Level Content Validity Index of the BCPA
Time Frame: At each Delphi round during an assessment period of approximately one month (maximum of four rounds).

The item-level content validity index (I-CVI) is the proportion of the 14 experts who rate a BCPA item as 3 (quite relevant) or 4 (highly relevant) on a four-point relevance scale. I-CVI will be calculated for each item during the Delphi process. Values range from 0 to 1, with higher values indicating greater expert agreement on item relevance.

At each Delphi round during an assessment period of approximately one month (maximum of four rounds).
Scale-Level Content Validity Indices of the BCPA
Time Frame: At completion of the Delphi content-validation process, approximately one month after the first round (maximum of four rounds).

Two scale-level content validity indices will be calculated for the final tool: S-CVI/Ave, the average of the item-level content validity indices, and S-CVI/UA, the proportion of items rated as 3 or 4 by all experts. Both indices range from 0 to 1, with higher values indicating greater content validity.

At completion of the Delphi content-validation process, approximately one month after the first round (maximum of four rounds).
Inter-Rater Agreement for Categorical BCPA Items
Time Frame: Day 1; the two independent assessments are completed within three hours.

Kappa will be calculated for each categorical BCPA item to assess agreement between ratings in 30 patients. Two medical staff members separately interview the same patient within three hours on the same day and independently record the answers.

Day 1; the two independent assessments are completed within three hours.
Inter-Rater Consistency for Continuous BCPA Items
Time Frame: Day 1; the two independent assessments are completed within three hours.

Intraclass correlation coefficients will be calculated for continuous BCPA items to assess consistency between ratings in 30 patients. Two medical staff members separately interview the same patient within three hours on the same day and independently record the answers.

Day 1; the two independent assessments are completed within three hours.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Patients With Meaningful Pain Relief Within or at 15 Minutes After Painkyl Administration
Time Frame: At the post-treatment BCPA assessment on Day 8-15, assessing meaningful pain relief within or at 15 minutes after Painkyl administration.

Patient-reported meaningful relief is assessed using BCPA Tool V1.2 item 9, which asks how long rescue medication takes to provide effective pain relief. At the post-treatment assessment, the medication is Painkyl. Responses of 10 minutes or less, or more than 10 but no more than 15 minutes, meet the endpoint. Responses of no effect or more than 15 minutes do not meet it. The percentage is the number of patients meeting the endpoint divided by the number of patients who received Painkyl, multiplied by 100.

At the post-treatment BCPA assessment on Day 8-15, assessing meaningful pain relief within or at 15 minutes after Painkyl administration.
Change in the Percentage of Patients Reporting Meaningful Pain Relief Within 15 Minutes From Pretreatment to Post-treatment
Time Frame: Pretreatment BCPA assessment on Day 0-1 and post-treatment BCPA assessment on Day 8-15.

The pretreatment and post-treatment percentages of patients reporting meaningful pain relief within 15 minutes will be compared using BCPA Tool V1.2 item 9. Responses of 10 minutes or less, or more than 10 but no more than 15 minutes, meet the relief criterion; no effect or more than 15 minutes does not. Pretreatment responses concern the existing rescue medication other than Painkyl; post-treatment responses concern Painkyl. The protocol defines evaluable patients as those with both pretreatment and post-treatment BCPA assessments, informed consent, eligibility, and no protocol violations. The protocol specifies a Cochran Q test for this comparison.

Pretreatment BCPA assessment on Day 0-1 and post-treatment BCPA assessment on Day 8-15.
Change From Pretreatment to Post-treatment in Usual Breakthrough Pain Intensity
Time Frame: Pretreatment BCPA assessment on Day 0-1 and post-treatment BCPA assessment on Day 8-15.

Usual breakthrough pain intensity is assessed using BCPA Tool V1.2 item 6: how painful the patient's breakthrough pain usually is. Patients select an integer from 0 to 10, where 0 means no pain and 10 means the worst pain; higher scores indicate greater pain intensity. Pretreatment and post-treatment scores will be compared. The questionnaire does not specify a fixed recall period. The protocol defines evaluable patients as those with both pretreatment and post-treatment BCPA assessments, informed consent, eligibility, and no protocol violations, and specifies generalized estimating equations (GEE) to examine the difference in pain intensity.

Pretreatment BCPA assessment on Day 0-1 and post-treatment BCPA assessment on Day 8-15.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Cheng-Hsu Wang, Chang Gung Memorial Hospital, Keelung

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2023

Primary Completion (Actual)

September 20, 2023

Study Completion (Estimated)

February 1, 2027

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 202301039A4

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.